Eltrombopag
Eltrombopag is an approved active ingredient.
Chemical compound
Boxed warning (US label)
RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C and RISK OF HEPATOTOXICITY In patients with chronic hepatitis C, ALVAIZ in combination with interferon and ribavirin may increase the risk of hepatic decompensation.
What it is used for
- Myelodysplastic syndrome
- Thrombocytopenia
- Anemia
- Autoimmune thrombocytopenic purpura
- Aplastic anemia
- Chronic hepatitis C
ALVAIZ is a thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 6 years and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
How it works
- Thrombopoietin receptor agonist
Common side effects
Hepatic Decompensation in Patients with Chronic Hepatitis C Hepatotoxicity Increased Risk of Death and Progression of Myelodysplastic Syndromes to Acute Myeloid Leukemia Thrombotic/Thromboembolic Complications Cataracts Across all indications, the most common adverse reactions (≥ 20% in any indication) were: anemia…
Pregnancy and breastfeeding
Available data from a small number of published case reports and postmarketing experience with eltrombopag use in pregnant women are insufficient to assess any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Interactions
- Simvastatin — muscular disease, rhabdomyolysis
- Cladribine
Brand names
United States
Alvaiz · Promacta · Promacta KIT
European Union
Eltrombopag Accord · Eltrombopag Viatris · Revolade
Canada
Apo-Eltrombopag · Jamp Eltrombopag · Revolade · Teva-Eltrombopag
Approval status
- US Food and Drug Administration
- prescription · since 2008
- European Medicines Agency
- authorised · since 2010
- Health Canada
- prescription · marketed
- First approval anywhere
- 2008
Codes
- ATC
- B02BX05
- RxNorm CUI
- 711942
- ChEMBL
- CHEMBL461101
- PubChem CID
- 135449332
- UNII
- S56D65XJ9G
- Wikidata
- Q411588
Frequently asked questions
What is Eltrombopag used for?
Eltrombopag is used for: Myelodysplastic syndrome, Thrombocytopenia, Anemia, Autoimmune thrombocytopenic purpura, Aplastic anemia, and Chronic hepatitis C.
What are the brand names of Eltrombopag?
Brand names of Eltrombopag include Alvaiz, Promacta, Promacta KIT, Eltrombopag Accord, Eltrombopag Viatris, Revolade, Apo-Eltrombopag, and Jamp Eltrombopag.
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)